<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176797</url>
  </required_header>
  <id_info>
    <org_study_id>LC2016PY034</org_study_id>
    <nct_id>NCT03176797</nct_id>
  </id_info>
  <brief_title>Quantitative Diagnosis of Liver Fibrosis on Multiparametric MRI</brief_title>
  <official_title>Quantitative Diagnosis of Liver Fibrosis on Multiparametric MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhujiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhujiang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early diagnosis and treatment of liver fibrosis can repress or delay the development of
      cirrhosis and hepatocellular carcinoma. The purpose of this pilot study is to evaluate
      non-invasive multiparametric magnetic resonance imaging (MRI) techniques in the detection and
      grading of liver fibrosis, so that patients can be treated in time. These techniques combined
      could reach high diagnostic performance for detection of liver fibrosis, and could decrease
      the number of liver biopsies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early diagnosis and treatment of liver fibrosis can repress or delay the development of
      cirrhosis and hepatocellular carcinoma. While liver biopsy is still considered the gold
      standard for diagnosing and assessing the presence and degree of liver fibrosis and
      inflammation, it has disadvantages including the potential for sampling error and risk of
      complications. New imaging modalities such as diffusion weighted imaging (DWI), intravoxel
      incoherent motion (IVIM), diffusion kurtosis imaging (DKI), T1ρ relaxation time (T1ρ), T1
      mapping of pre-contrast and hepatocyte phase using hepatocyte specific agent and
      susceptibility weighted imaging (SWI) allow non-invasive evaluation of liver parenchymal
      characteristics and may be able to detect and quantify parenchymal fibrosis alleviating the
      need for biopsy. Patients with chronic liver disease or normal liver parenchyma who are
      scheduled to undergo either liver resection or liver biopsy are included. Referred patients
      undergo multiparametric MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and
      hepatocyte phase and SWI before surgery or biopsy. The pathologic changes are evaluated using
      multiparametric MRI, and compared between normal/early fibrosis and advanced fibrosis. To
      explore if combine these techniques could reach higher diagnostic performance for detection
      and grading of liver fibrosis. This project will provide a reliable and noninvasive method
      for the monitoring stage of liver fibrosis and therapeutic evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI T1ρ T1mapping SWI and DWI</measure>
    <time_frame>MRI within 3 months of liver biopsy or surgery</time_frame>
    <description>Quantitative Diagnosis accuracy of MRI in the degree of fibrosis and advanced fibrosis compared with histology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI T1ρ T1mapping SWI and DWI</measure>
    <time_frame>Blood Test taken on same day as MRI</time_frame>
    <description>Quantitative Diagnosis accuracy of MRI in the degree of fibrosis and advanced fibrosis compared with serological markers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Liver Fibrosis</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Liver MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Liver MRI</intervention_name>
    <description>Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.</description>
    <arm_group_label>Liver MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic liver disease (viral hepatitis, alcoholic hepatitis, or other...)

          -  AND willingly able to complete all research procedures and follow the entire research
             process

          -  AND scheduled for liver resection or biopsy

          -  AND signed informed consent

        Exclusion Criteria:

          -  Any contraindication for contrast-enhanced MRI

          -  Pregnant or nursing women

          -  Any organ transplant history, and existing functional grafts (except corneal or fur
             grafts)

          -  Recent right upper quadrant patients with traumatic healed

          -  A serious history of illness or other evidence of a serious illness or suffering from
             any other disease

          -  Patients who have been enrolled in other interventional clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianyue Quan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern Medical University, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZhuJiang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510280</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Kobayashi K, Nakao H, Nishiyama T, Lin Y, Kikuchi S, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Satoh K, Nakade Y, Ito K, Yoneda M. Diagnostic accuracy of real-time tissue elastography for the staging of liver fibrosis: a meta-analysis. Eur Radiol. 2015 Jan;25(1):230-8. doi: 10.1007/s00330-014-3364-x. Epub 2014 Aug 23. Review.</citation>
    <PMID>25149296</PMID>
  </results_reference>
  <results_reference>
    <citation>Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010 Sep 9;10:103. doi: 10.1186/1471-230X-10-103.</citation>
    <PMID>20828377</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang YX, Yuan J, Chu ES, Go MY, Huang H, Ahuja AT, Sung JJ, Yu J. T1rho MR imaging is sensitive to evaluate liver fibrosis: an experimental study in a rat biliary duct ligation model. Radiology. 2011 Jun;259(3):712-9. doi: 10.1148/radiol.11101638. Epub 2011 Mar 24.</citation>
    <PMID>21436087</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao F, Wang YX, Yuan J, Deng M, Wong HL, Chu ES, Go MY, Teng GJ, Ahuja AT, Yu J. MR T1ρ as an imaging biomarker for monitoring liver injury progression and regression: an experimental study in rats with carbon tetrachloride intoxication. Eur Radiol. 2012 Aug;22(8):1709-16. doi: 10.1007/s00330-012-2419-0. Epub 2012 Mar 27.</citation>
    <PMID>22752522</PMID>
  </results_reference>
  <results_reference>
    <citation>Girometti R, Furlan A, Esposito G, Bazzocchi M, Como G, Soldano F, Isola M, Toniutto P, Zuiani C. Relevance of b-values in evaluating liver fibrosis: a study in healthy and cirrhotic subjects using two single-shot spin-echo echo-planar diffusion-weighted sequences. J Magn Reson Imaging. 2008 Aug;28(2):411-9. doi: 10.1002/jmri.21461.</citation>
    <PMID>18666139</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu G, Chan Q, Quan X, Zhang X, Li Y, Zhong X, Lin X. Intravoxel incoherent motion MRI evaluation for the staging of liver fibrosis in a rat model. J Magn Reson Imaging. 2015 Aug;42(2):331-9. doi: 10.1002/jmri.24796. Epub 2014 Nov 11.</citation>
    <PMID>25384923</PMID>
  </results_reference>
  <results_reference>
    <citation>Shiha G, Ibrahim A, Helmy A, Sarin SK, Omata M, Kumar A, Bernstien D, Maruyama H, Saraswat V, Chawla Y, Hamid S, Abbas Z, Bedossa P, Sakhuja P, Elmahatab M, Lim SG, Lesmana L, Sollano J, Jia JD, Abbas B, Omar A, Sharma B, Payawal D, Abdallah A, Serwah A, Hamed A, Elsayed A, AbdelMaqsod A, Hassanein T, Ihab A, GHaziuan H, Zein N, Kumar M. Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017 Jan;11(1):1-30. doi: 10.1007/s12072-016-9760-3. Epub 2016 Oct 6.</citation>
    <PMID>27714681</PMID>
  </results_reference>
  <results_reference>
    <citation>Petitclerc L, Sebastiani G, Gilbert G, Cloutier G, Tang A. Liver fibrosis: Review of current imaging and MRI quantification techniques. J Magn Reson Imaging. 2017 May;45(5):1276-1295. doi: 10.1002/jmri.25550. Epub 2016 Dec 16. Review.</citation>
    <PMID>27981751</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu G, Zhang X, Liang W, Zhong X, Chan Q, Lin X, Lin T, Li Y, Quan X. Assessment of liver fibrosis in rats by MRI with apparent diffusion coefficient and T1 relaxation time in the rotating frame. J Magn Reson Imaging. 2016 May;43(5):1082-9. doi: 10.1002/jmri.25084. Epub 2015 Oct 26.</citation>
    <PMID>26497954</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhujiang Hospital</investigator_affiliation>
    <investigator_full_name>Quan Xianyue</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Liver Fibrosis, multiparametric magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

